QuidelOrtho delivered solid performance in Q3 with organic sales growth of 5%, excluding COVID sales and the U.S. Donor screening business. Adjusted EBITDA margin expanded to 25% of sales, driven by margin improvement initiatives and cost savings of over $40 million. Revenue in Labs grew 4%, immunohematology grew 5%, and Point of Care grew 7%. North America revenue was down 12% but up 5% year over year, excluding respiratory revenue and U.S. Donor screening exit. International markets showed growth, with Latin America up 21% and EMEA up 3%. Adjusted EBITDA was $177 million, a 180 basis point year-over-year improvement. Adjusted diluted EPS was $0.80. QuidelOrtho is focused on sustainable profitable growth and margin expansion. They are encouraged by progress made and confident in the future.

Brian J. Blaser, CEO of QuidelOrtho, discussed the company’s strong performance in Q3, highlighting organic sales growth of 5% and significant improvements to adjusted EBITDA margin, expanding to 25% of sales. QuidelOrtho reported revenue growth in Labs, immunohematology, and Point of Care businesses, with strong demand from blood banks and hospitals. While North America revenue was down, international markets showed growth. Adjusted EBITDA was $177 million, a 180 basis point year-over-year improvement. QuidelOrtho remains focused on cost savings initiatives, strategic investments, and sustainable profitable growth.

In Q3, QuidelOrtho reported solid performance with organic sales growth of 5% and significant improvements to adjusted EBITDA margin, expanding to 25% of sales. Revenue growth was seen in Labs, immunohematology, and Point of Care businesses, with strong demand from blood banks and hospitals. North America revenue was down 12% but up 5% year over year, excluding respiratory revenue and the U.S. Donor screening exit. International markets, particularly Latin America, showed strength with 21% growth. Adjusted EBITDA was $177 million, a 180 basis point year-over-year improvement. QuidelOrtho remains focused on sustainable profitable growth and margin expansion.

QuidelOrtho reported a strong performance in Q3, with organic sales growth of 5% and significant improvements to adjusted EBITDA margin, expanding to 25% of sales. Revenue growth was seen in Labs, immunohematology, and Point of Care businesses, with notable demand from blood banks and hospitals. Despite a decline in North America revenue, international markets, especially Latin America, showed growth. Adjusted EBITDA was $177 million, a 180 basis point year-over-year improvement. QuidelOrtho remains focused on strategic investments, cost savings initiatives, and sustainable profitable growth.

Read more at Yahoo Finance.: QuidelOrtho (QDEL) Q3 2025 Earnings Transcript